Sandbox:staging: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
|||
Line 87: | Line 87: | ||
* '''Intermediate risk neuroblastoma groups''' include: | * '''Intermediate risk neuroblastoma groups''' include: | ||
:* Patients with stage 1 tumor irrespective of the age, grade, and molecular pathway. | :* Patients with stage 1 tumor irrespective of the age, grade, and molecular pathway. | ||
Group 2 | |||
2A/2B (<50% resected or Bx only) | |||
0–12 years | |||
MYCN-NA, any histology/ploidy* | |||
3 | |||
<365 days | |||
MYCN-NA, FH, DI>1* | |||
3 | |||
≥365 days - 12 years | |||
MYCN-NA, FH* | |||
4S (symptomatic) | |||
<365 days | |||
MYCN-NA, FH, DI>1* | |||
Group 3 | |||
3 | |||
<365 days | |||
MYCN-NA, either UH or DI=1* | |||
4 | |||
<365 days | |||
MYCN-NA, FH, DI>1* | |||
4S | |||
<365 days | |||
MYCN-NA, either UH or DI=1*; or unknown biology | |||
Group 4 | |||
4 | |||
<365 days | |||
MYCN-NA, either DI=1 or UH | |||
3 | |||
365 -<547 days | |||
MYCN-NA, UH, any ploidy | |||
4 | |||
365 -<547 days | |||
MYCN-NA, FH, DI>1 | |||
* '''High risk neuroblastoma groups''' include: | |||
2A/2B, 3, 4, 4S | |||
Any | |||
MYCN-amplified, any histology/ploidy | |||
3 | |||
≥ 547 days | |||
MYCN-NA, UH, any ploidy | |||
4 | |||
365 - >547 days | |||
MYCN-NA, UH or DI=1 | |||
4 | |||
> 547 days | |||
Any |
Revision as of 13:46, 7 October 2015
Neuroblastoma Staging
International Neuroblastoma Staging System (INSS)
The staging of neuroblastoma is based on the International Neuroblastoma Staging System (INSS).[1]
T | Description |
Stage 1 |
|
Stage 2A |
|
Stage 2B |
|
Stage 3 |
|
Stage 4 |
|
Stage 4S |
|
International Neuroblastoma Risk Group Staging System (INRGSS)
Stage: | Description |
Stage L1 |
|
Stage L2 |
|
Stage M |
|
Stage MS |
|
Risk Stratification
- Neuroblastoma patients are risk stratified into a low risk group, an intermediate risk group, and a high risk group based on the tumor INSS stage, tumor grade the patient's age, and the molecular pathway involved.
- Low risk neuroblastoma groups include:
- Patients with stage 1 tumor irrespective of the age, grade, and molecular pathway.
- Patients with stage 2A/2B, irrespective of age, irrespective of grade, MYCN-NA molecular pathway
- Patients with Stage 4S, <365 days of age, favorable histology, DNA Index >1 , MYCN-NA molecular pathway
- Intermediate risk neuroblastoma groups include:
- Patients with stage 1 tumor irrespective of the age, grade, and molecular pathway.
Group 2
2A/2B (<50% resected or Bx only) 0–12 years MYCN-NA, any histology/ploidy* 3 <365 days MYCN-NA, FH, DI>1* 3 ≥365 days - 12 years MYCN-NA, FH* 4S (symptomatic) <365 days MYCN-NA, FH, DI>1*
Group 3
3 <365 days MYCN-NA, either UH or DI=1* 4 <365 days MYCN-NA, FH, DI>1* 4S <365 days MYCN-NA, either UH or DI=1*; or unknown biology
Group 4
4 <365 days MYCN-NA, either DI=1 or UH 3 365 -<547 days MYCN-NA, UH, any ploidy 4 365 -<547 days MYCN-NA, FH, DI>1
- High risk neuroblastoma groups include:
2A/2B, 3, 4, 4S
Any
MYCN-amplified, any histology/ploidy
3
≥ 547 days
MYCN-NA, UH, any ploidy
4
365 - >547 days
MYCN-NA, UH or DI=1
4
> 547 days
Any
- ↑ Neuroblastoma. Wikipedia (2015) https://en.wikipedia.org/wiki/Neuroblastoma Accessed on October, 5 2015